Shanghai Yizhong Pharmaceutical (688091) Stock Overview
Shanghai Yizhong Pharmaceutical Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
688091 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Shanghai Yizhong Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥54.00 |
| 52 Week High | CN¥83.60 |
| 52 Week Low | CN¥33.34 |
| Beta | -0.33 |
| 1 Month Change | -11.24% |
| 3 Month Change | 4.27% |
| 1 Year Change | 48.03% |
| 3 Year Change | -16.97% |
| 5 Year Change | n/a |
| Change since IPO | 114.37% |
Recent News & Updates
Recent updates
Subdued Growth No Barrier To Shanghai Yizhong Pharmaceutical Co., Ltd. (SHSE:688091) With Shares Advancing 27%
Nov 20
We Think You Can Look Beyond Shanghai Yizhong Pharmaceutical's (SHSE:688091) Lackluster Earnings
Nov 08There's Reason For Concern Over Shanghai Yizhong Pharmaceutical Co., Ltd.'s (SHSE:688091) Massive 34% Price Jump
Oct 01Is Shanghai Yizhong Pharmaceutical (SHSE:688091) Using Too Much Debt?
Aug 20What Shanghai Yizhong Pharmaceutical Co., Ltd.'s (SHSE:688091) P/E Is Not Telling You
Jul 24Concerns Surrounding Shanghai Yizhong Pharmaceutical's (SHSE:688091) Performance
Apr 15Getting In Cheap On Shanghai Yizhong Pharmaceutical Co., Ltd. (SHSE:688091) Is Unlikely
Mar 29Shareholder Returns
| 688091 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 10.5% | 0.2% | -1.4% |
| 1Y | 48.0% | 18.0% | 28.9% |
Return vs Industry: 688091 exceeded the CN Pharmaceuticals industry which returned 18% over the past year.
Return vs Market: 688091 exceeded the CN Market which returned 28.9% over the past year.
Price Volatility
| 688091 volatility | |
|---|---|
| 688091 Average Weekly Movement | 8.0% |
| Pharmaceuticals Industry Average Movement | 4.2% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in CN Market | 9.7% |
| 10% least volatile stocks in CN Market | 3.1% |
Stable Share Price: 688091's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 688091's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 415 | Jingsong Zhou | www.yizhongpharma.com |
Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the development of anti-tumor drugs and related products in China. It also offers paclitaxel polymer nanomicelles for the treatment of non-small cell lung cancer, as well as various types of cancer, including esophageal cancer, gastric cancer, nasopharyngeal carcinoma, pancreatic cancer, breast cancer, gynecological tumors, etc. The company was founded in 2009 and is headquartered in Shanghai, China.
Shanghai Yizhong Pharmaceutical Co., Ltd. Fundamentals Summary
| 688091 fundamental statistics | |
|---|---|
| Market cap | CN¥11.09b |
| Earnings (TTM) | CN¥64.13m |
| Revenue (TTM) | CN¥317.08m |
Is 688091 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688091 income statement (TTM) | |
|---|---|
| Revenue | CN¥317.08m |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥317.08m |
| Other Expenses | CN¥252.94m |
| Earnings | CN¥64.13m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Apr 28, 2026
| Earnings per share (EPS) | 0.31 |
| Gross Margin | 100.00% |
| Net Profit Margin | 20.23% |
| Debt/Equity Ratio | 0% |
How did 688091 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/09 02:29 |
| End of Day Share Price | 2026/02/09 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shanghai Yizhong Pharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.